Frontiers in Pharmacology | Pharmacoepidemiology

Original Research

Accepted on 21 Feb 2025

Real-World Safety Profile of Elexacaftor/Tezacaftor/Ivacaftor: A Disproportionality Analysis Using the U.S. FDA Adverse Event Reporting System

in Pharmacoepidemiology

Chengyu Zhu
Zhiwei Cui
Tingting Liu
Siyu Lou
Linmei Zhou
Junyou Chen
Ruizhen Zhao
Li Wang
Yingyong Ou
Fan Zou

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1531514

Original Research

Published on 19 Feb 2025

Impact of levetiracetam on direct oral anticoagulant level and outcomes among older Asian patients with atrial fibrillation

in Pharmacoepidemiology

Yu-Ting Huang
Tzu-Ling Chen
Yun-Lin Huang
Ching-Hua Kuo
Yu-Fong Peng
Sung-Chun Tang
Jiann-Shing Jeng
Chih-Feng Huang
Shin-Yi Lin
Fang-Ju Lin

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1505665

321 views

Original Research

Published on 18 Feb 2025

Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database

in Pharmacoepidemiology

Fang Wu
Siliang Wang
Xihui Xu
Weihui Zhang
Jie Zhou
Runyan Niu
Wenting Cai
Yonggong Yang
Mengying Liu
Jinping Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1459067

181 views

Original Research

Accepted on 17 Feb 2025

Non-Chemotherapy Drugs Inducing Agranulocytosis: A Disproportionality Analysis Based on the FAERS Database

in Pharmacoepidemiology

Shanshan Wu
Lina Huang
Jiajia Chen
Xiaochun Xie
Shaokai Huang
Xiaojie Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1525307

Original Research

Published on 17 Feb 2025

Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis

in Pharmacoepidemiology

Long He
Jinwei Li
Xiong Cheng
Li Luo
Yilan Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1509561

204 views

Review

Accepted on 13 Feb 2025

A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX

in Pharmacoepidemiology

Ralf J Ludwig
Matthew Anson
Henner Zirpel
Diamant Thaci
Henning Olbrich
Katja Bieber
Khalaf Kridin
Astrid Dempfle
Philip Curman
Sizheng S Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1516126

188 views

Original Research

Accepted on 13 Feb 2025

Signal Detection and Safety Analysis of Three Tyrosine Kinase Inhibitors for HER-2 Positive Breast Cancer: A Retrospective Study Based on the FAERS Database

in Pharmacoepidemiology

Xiting Tang
ChengLiang Wang
Yanwei Li
Jing Tang
Guoping Zhang
Li Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1538881

Original Research

Published on 13 Feb 2025

Real-world pharmacovigilance investigation of imipenem/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database

in Pharmacoepidemiology

Peng Jia
Yusen Zhou
Yuan Gao
Shangyu Wang
Jiangliu Yin
Yixiang Lian
Quanyou Lai

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1524159

157 views

Original Research

Published on 13 Feb 2025

Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database

in Pharmacoepidemiology

Fengqi Zhou
Haiou He
Zhen Zhang
Jing Gao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1488469

127 views

Original Research

Accepted on 12 Feb 2025

Development of a Core Outcome Set for Pharmacological Interventions in Osteoporosis among Patients with Diabetes Mellitus: An International Consensus Study Protocol

in Pharmacoepidemiology

Chao Wei
Xiaobin Wang
Zubing Mei
Jing Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1510968

Original Research

Published on 11 Feb 2025

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system

in Pharmacoepidemiology

Shiyi Wang
Xiaojian Wang
Jing Ding
Xudong Zhang
Hongmei Zhu
Yihong Fan
Changbo Sun

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1436183

215 views

Correction

Published on 07 Feb 2025

Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database

in Pharmacoepidemiology

Xi-Feng Wang
Lu-Ri Bao
Ta-La Hu
Rui-Feng Xu
Wu-Niri Gao
Jing-Yuan Wang
Jian-Rong Zhao
Zhen-Li Fu
Shu-Fang Wang
Yan Meng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1558930

223 views

Systematic Review

Accepted on 05 Feb 2025

Is tranexamic acid effective for all traumatic brain injury patients? A Severity Based Systematic Review and Meta-Analysis

in Pharmacoepidemiology

Wentao Bian
Wenkai Bian
Yixuan Lu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1472232

Original Research

Published on 29 Jan 2025

Exploring the association between herbal medicine usage and drug-induced liver injury: insights from a nationwide population-based cohort study using SCCS in South Korea

in Pharmacoepidemiology

Taehyun Yang
Juhee Ahn
Sungho Won
Sanghun Lee

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1498124

2,555 views

Original Research

Published on 24 Jan 2025

Data mining and safety analysis of voriconazole in patients with a hematological malignant tumor based on the FAERS database: differences between children and adults

in Pharmacoepidemiology

Hao Li
Manxue Jiang
Xiaona Pan
Lingti Kong

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1524702

475 views

Systematic Review

Published on 23 Jan 2025

Global bibliometric analysis of traditional Chinese medicine regulating gut microbiota in the treatment of diabetes from 2004 to 2024

in Pharmacoepidemiology

Jieling Liang
Xiaojuan Lin
Xin Liao
Xi Chen
Ying Zhou
Lin Zhang
Yunyun Qin
Haoru Meng
Zhongwen Feng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1533984

714 views

Navigation group

Articles

Real-World Safety Profile of Elexacaftor/Tezacaftor/Ivacaftor: A Disproportionality Analysis Using the U.S. FDA Adverse Event Reporting System

Impact of levetiracetam on direct oral anticoagulant level and outcomes among older Asian patients with atrial fibrillation

Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database

Non-Chemotherapy Drugs Inducing Agranulocytosis: A Disproportionality Analysis Based on the FAERS Database

Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis

A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX

Signal Detection and Safety Analysis of Three Tyrosine Kinase Inhibitors for HER-2 Positive Breast Cancer: A Retrospective Study Based on the FAERS Database

Real-world pharmacovigilance investigation of imipenem/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database

Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database

Development of a Core Outcome Set for Pharmacological Interventions in Osteoporosis among Patients with Diabetes Mellitus: An International Consensus Study Protocol

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system

Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database

Is tranexamic acid effective for all traumatic brain injury patients? A Severity Based Systematic Review and Meta-Analysis

Exploring the association between herbal medicine usage and drug-induced liver injury: insights from a nationwide population-based cohort study using SCCS in South Korea

Data mining and safety analysis of voriconazole in patients with a hematological malignant tumor based on the FAERS database: differences between children and adults

Global bibliometric analysis of traditional Chinese medicine regulating gut microbiota in the treatment of diabetes from 2004 to 2024